secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenetic Biosciences, Inc. (XBIO)
CIK:        0001534525
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001683168-23-007922
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenetic Biosciences reports Q3 net loss of $1.1M; R&D spend up 156% on DNase platform
--------------------------------------------------------------------------------

- Net loss of $1.1M for Q3 2023; cash at $9.8M.
- R&D expenses rose 155.9% to $1.0M on DNase platform preclinical work.
- Royalty income from Takeda sublicense up 47.5% to $0.6M.
- Advancing DNase platform toward first-in-human study for pancreatic carcinoma.
- G&A expenses down 14.6% to $0.7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534525/000168316823007922/0001683168-23-007922-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534525/000168316823007922/xenetic_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-007922

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer